| Name | Designation | Main Interest |
| Dr. Arun B. Shah | Emeritus Professor | Stroke, Thrombolysis in stroke, Neuroimaging |
| Dr. Rahul Chakor | Lecturer | Epilepsy, Behavioral Neurology |
| Dr. Haresh Bharote | Lecturer | |
| Mrs. Nola Shah | EEG Technician | |
| Mrs. Kavita S. Shetty | Jr. Stenographer | |
| Dr. Ramshkekhar Menon Dr. Mahendra Javali Dr. Anand Soni |
Senior Residents |
| Day | Morning | Afternoon | Evening |
| Monday | Epilepsy clinic | Evaluation of admitted pts by Residents and Lecturer on call EEG Reporting |
Rounds with medicine and pscyhiatry residents |
| Tuesday | Neurology OPD (New Cases) |
Evaluation of admitted pts by Residents and Lecturer on call EMG Nerve conduction studies |
Clinic for Medicine and psychiatry residents |
| Wednesday | Grand rounds of male female ward Intensive care unit and references with all staff members | EMG nerve conduction studies | Rounds with medicine and psychiatry residents |
| Thursday | Neurology OPD (Follow-up) |
Evaluation of admitted pts. by Residents and Lecturer on call EMG Nerve conduction studies |
Tutorial for medicine and psychiatry residents |
| Friday | Rounds with lecturers of male and female ward Intensive care unit and references | Neuro-Radiology Meeting Seminar |
Rounds with the medicine and psychiatry residents |
| Saturday | Rounds with Lecturers | Journal club EEG Reporting |
Review of admitted cases |
| Day | Lecture | Timing |
| Monday | Undergraduate Medical studies (MBBS) | 8.30 am to 9.30 am |
| Tuesday | Audiology and speech therapy | 8.30 am to 9.30 am |
| Wednesday | Occupational and physio therapy | 2.30 pm to 3.30 pm |
| Thursday | Medicine postgraduate case presentation | 2.30 pm to 3.30 pm |
| Friday | Occupational and physio therapy | 2.30 pm to 3.30 pm |
| A Randomized, Multicenter, Double-Blind, Placebo- Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of investigational drug in Subjects with Relapsing-Remitting Multiple Sclerosis. | |
| An International, randomized, double-blind, parallel, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of brivaracetam in subjects (> 16 to 70 years old )suffering from localization related or generalized epilepsy". | |
| An Open-label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 150 mg/day in subjects aged 16 years or older suffering from epilepsy. | |
| Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with investigation drug in patients with a history of ischaemic stroke or transient ischaemic stroke-The PERFORM study. | |
| A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable dose of Dopamine Agonist and/or Anticholinergic. | |
| A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the long-term efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of Safinamide, as add-on therapy, in patients with idiopathic Parkinson's disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of dopamine agonist and/or an anticholinergic. | |
| Age Related Cognitive Loss in Mumbai, India. | |
| A Randomised, Double-blind, Placebo-controlled, Parallel-Group, Multicentre study to Evaluate the Efficacy, Safety, and Tolerability of investigational drug as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-label Extension study. |
| A Multicentre, Randomized, Double-blind, Placebo controlled, Parallel Group Study of the Efficacy , Safety and Tolerability of investigational drug in Levodopa Treated Parkinson's Disease Patients with Motor Fluctuations. | |
| A 16-week, Double blind, Placebo-Controlled, Randomised, Parallel Group, Multicentre, International Study to Evaluate the Efficacy and Safety of investigational drug and that of Entacapone versus Placebo as treatment for Parkinson's Disease in patients with Motor Response Complications on Levodopa Therapy. | |
| A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 to 40 mg/d Doses of (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Resonse Complications on Levodopa Therapy. | |
| A multicenter, randomized, Double-blind, Parallel-group placebo and pramipexole controlled Study to Assess Efficacy and Safety of investigational drug Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease. |
| Effect of -Secretase Inhibition on the Progression of Alzheimer's Disease. | |
| A Phase III, double blind, placebo controlled randomized trial to determine the efficacy and safety of a low (50mg/day) and high (100mg/day) dose of safinamide, as add-on therapy, in subjects with early idiopathic Parkinson's Disease treated with a stable dose of a single dopamine agonist. | |
| A Phase III, double blind, placebo controlled randomized trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as an add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine. | |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, with Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the Cogstate Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients Randomized to Either Donepezil or Placebo. |
| Establishment of "Comprehensive Epilepsy Care Unit" and presurgical evaluation for patients with refractory epilepsy. | |
| Establishment of a dedicated Stroke Unit. |